Who is sponsoring NCT06115460?

NCT06115460 is sponsored by Ain Shams University.

What drugs are being tested in NCT06115460?

Interventions in NCT06115460: oral sitagliptin supplementation.

What condition does NCT06115460 study?

NCT06115460 studies Type 1 Diabetic Nephropathy.

Is NCT06115460 still recruiting?

NCT06115460 is currently completed. Last updated 7 November 2023.

Last reviewed 2023-11-07 · How we verify

NCT06115460

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Impact of Sitagliptin as an Add on Therapy With Closed Loop Control in Adolescents With Diabetic Nephropathy

Completed Phase 3 Last updated 7 November 2023

What this trial tests

Phase 3 trial testing oral sitagliptin supplementation in Type 1 Diabetic Nephropathy in 46 participants. Completed in 15 June 2023.

Timeline

1 March 2022

Primary endpoint
1 June 2023

15 June 2023

Quick facts

Lead sponsor	Ain Shams University
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	46
Start date	1 March 2022
Primary completion	1 June 2023
Estimated completion	15 June 2023
Sites	1 location across Egypt

Drugs / interventions tested

oral sitagliptin supplementation — full drug profile →

Conditions studied

Type 1 Diabetic Nephropathy — all drugs for Type 1 Diabetic Nephropathy →

Sponsor

Ain Shams University

Who can join

Adults 12 to 18, any sex, with Type 1 Diabetic Nephropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Diabetic nephropathy (DN) is one of the most frequent microvascular complications of diabetes mellitus, affecting 25 to 40% of patients with type 1 diabetes (T1DM). Early diagnosis, appropriate patient follow-up and treatment are essential to improve the outcomes. There is a need for improvements in insulin therapy for people with T1DM as the majority of patients are struggling to achieve glycemic targets. Technological advancements and oral adjuncts to insulin therapies are starting to be licensed for the use of people with T1DM. Dipeptidyl peptidase-4 (DPP-4), a multifunctional serine protease with a dual function (regulatory protease and binding protein), can modulate inflammation and immune cell-mediated β-cell destruction. DPP-4 degrades the peptide hormones glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP). Several studies have suggested that the upregulated DPP-4 activity is correlated with T1DM pathophysiology.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial.
Elbarbary NS, Ismail EA, El-Hamamsy MH, Ibrahim MZ, et al · · 2024 · cited 6× · PMID 39271520 · DOI 10.1007/s00125-024-06265-7

Verify or expand the search:

Other Ain Shams University trials

Trials by the same sponsor.

NCT07435493 — Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstru · NA · not yet recruiting
NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting
NCT07531030 — Posterior Pericapsular Deep Gluteal Block Combined With Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blo · NA · not yet recruiting
NCT06839027 — Arterial to Central co2gap in Relation to Outcome After Cardiopulmonary Bypass · not yet recruiting
NCT07516535 — DISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06115460 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ain Shams University
Last refreshed: 7 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06115460.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing